EP1963254A2 - Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride - Google Patents

Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride

Info

Publication number
EP1963254A2
EP1963254A2 EP06842760A EP06842760A EP1963254A2 EP 1963254 A2 EP1963254 A2 EP 1963254A2 EP 06842760 A EP06842760 A EP 06842760A EP 06842760 A EP06842760 A EP 06842760A EP 1963254 A2 EP1963254 A2 EP 1963254A2
Authority
EP
European Patent Office
Prior art keywords
lercanidipine hydrochloride
lercanidipine
solution
preparation
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06842760A
Other languages
German (de)
French (fr)
Inventor
Shrinivas Rao A.V.V.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Torrent Pharmaceuticals Ltd
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of EP1963254A2 publication Critical patent/EP1963254A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains

Definitions

  • the present invention relates to new, improved and industrially viable process for the preparation of Lercanidipine or its pharmaceutically acceptable salts using novel derivatives of 2,N-dimethyl-N-(3,3-diphenylpropyl)-l -amino compounds and novel process for the preparation of amorphous Lercanidipine hydrochloride.
  • Lercanidipine hydrochloride i.e., 3,5-Pyridinedicarboxylic acid, l,4-dihydro-2,6- dimethyl-4-(3-nitrophenyl)-,2-[(3,3-diphenylpropyl)methylamino]- 1 , 1 -dimethyl ester, hydrochloride having the formula (I)
  • Lercanidipine hydrochloride (I) is disclosed in US4705797.
  • crude lercanidipine is obtained as an oily residue that must be purified by flash chromatography using chloroform, containing increasing amounts of acetone, as the eluant.
  • the solvent is then evaporated to dryness and remaining residue is dissolved in methanol adding a small excess of hydrochloric acid in ethanol.
  • the hemi-hydrated hydrochloride salt is prepared by treatment with diluted hydrochloric acid in the presence of sodium chloride.
  • US Patent No. 5912351 describes an alternate process for the preparation of lercanidipine hydrochloride. It involves reaction of 1, 4-dihydro-2, 6-dimethyl-5- methoxycarbonyl-4- (3-nitrophenyl) pyridine-3-carboxylic acid with thionyl chloride in dichloromethane and dimethylformamide at a temperature between -4° and +1 0 C and subsequent esterification of the obtained acid chloride with 2, N-dimethyl-N- (3, 3 diphenylpropyl)-l-arnino-2-propyl alcohol at a temperature between -10° and O 0 C.
  • the disadvantage of the said process is the use of thionyl chloride as a reactant, which is difficult to handle on an industrial scale because of evolution of sulphur dioxide and hydrochloric gas from the reaction. Moreover it also requires special grade of equipment such as glass-lined reactor etc.
  • the Applicant has found simpler and cost-effective process for synthesizing Lercanidipine, avoiding use of hazardous materials, which is industrially viable and gives better yields.
  • WO/03/014084 discloses novel crystalline form I & II of Lercanidipine Hydrochloride and mixtures of Form I & II having predetermined and reproducible content of Form I & II & optionally other forms of Lercanidipine Hydrochloride such as amorphous.
  • EP 1600441 discloses crystalline form I of Lercanidipine Hydrochloride and a mixture of form I with amorphous and optionally form II.
  • these prior art don't describe pure amorphous form (anhydrous or hemihydrate) of Lercanidipine Hydrochloride and its preparation.
  • WO2006089787A1 discloses process for the preparation of pure amorphous lercanidipine hydrochloride from crystalline lercanidipine hydrochloride.
  • the present invention provides obvious benefits with respect to removing both the technical problems associated with prior art as well being simpler and economical, while at the same time achieving high purity and yield of the product with convenience to operate on a commercial scale.
  • the present invention relates to new, improved and industrially viable process for the preparation of Lercanidipine hydrochloride using novel intermediate of amino phenyl derivatives of formula (III) with 1,4-dihydropyridine acid derivative.
  • R is X OrOSO 2 R
  • X Cl, F, Br or I ;
  • R alkyl (C 1 to C 4) , phenyl, or 4-methyl phenyl.
  • the object of the present invention is to provide a new and improved process for synthesis of Lercanidipine hydrochloride.
  • the second object of the instant invention is to provide a simpler and cost-effective process for synthesis of Lercanidipine hydrochloride.
  • Another object of the present invention is to provide an industrially viable process for synthesis of Lercanidipine hydrochloride.
  • Still another object of the present invention is to provide an improved process for synthesis of Lercanidipine hydrochloride, which gives better yield.
  • Yet another object of the present invention is to provide novel polymorphic forms of Lercanidipine hydrochloride and process for the preparation thereof.
  • Yet another object of the present invention is to provide novel process for amorphous form of Lercanidipine hydrochloride.
  • the present invention provides a process for the preparation of lercanidipine hydrochloride of formula (I) as described herein below:
  • Fig. 1 This figure indicates X-ray diffraction pattern of amorphous Form Tl of Lercanidipine hydrochloride obtained according to the present invention.
  • Fig. 2 This figure indicates Infrared Spectrum of amorphous Form Tl Lercanidipine hydrochloride obtained according to the present invention.
  • Fig. 3 This figure indicates Differential Scaning Calorimetry of amorphous Form Tl Lercanidipine hydrochloride obtained according to the present invention.
  • an efficient process for the preparation of Lercanidipine which provides obvious benefits with respect to economics, generation of minimal effluents, lesser number of process steps, less reactor occupancy, higher purity of the product with convenience to operate on a commercial scale.
  • the present invention provides an improved process for preparing Lercanidipine Hydrochloride (I) as discussed herein: -
  • Reaction B -(a) (a') Reacting 2,N-Dimethyl-N-(3,3-diphenyl propyl)-l-amino-2-propanol Formula ( II ) with Halogenating agent in suitable solvent or mixture thereof to obtained, of N- Dimethyl-N- (3,3-diphenyl propyl)- l-amino-2-halide compound (IHB)
  • X Cl, Br, F, or I.
  • X chloride
  • R" thionyl chloride, Phosphorous oxychloride, Oxaloylchloride, phosphorous trichloride or phosphorous pentachloride.
  • Reaction B-(a) can be carried out using by methane sulphonyl halide, p-toluene sulphonyl chloride, or benzene sulphonyl chloride using base selected from the group comprising of organic base, inorganic bases.
  • organic and inorganic bases are triethylamine, pyridine, sodium hydroxide and potassium hydroxide, sodium carbonates, and the like, at temperature ranging from about -15°C. to 60°C, preferably between -5°C. to 25 0 C, more preferably between 5°C. to 2O 0 C, optionally in an inert gas atmosphere.
  • the duration of the esterification reaction may be from 15 minutes to 5 hours depending on reagents used and measuring end point of reaction by analytical method such as TLC, HPLC and the like.
  • Reaction B-(a') can be carried out by using thionyl chloride, Phosphorous oxichloride, oxalylchloride, phosphorous trichloride or phosphorous pentachloride at temperature ranging from about 15 0 C. to 60°C, preferably between 2O 0 C. to 45°C, more preferably between 25 0 C. to 40°C, optionally in an inert gas atmosphere. The duration of the reaction may be from 15 minutes to 5 hours.
  • Reaction (C) as per the present invention can be carried out using in general by reacting compound (IIIB) with 2,6-dimethyl-5-methoxy carbonyl-4-(3-nitrophenyl)- l,4-dihydropyridine-3-carboxylic acid of formula (IV) using base selected from the group comprising of organic base, inorganic bases.
  • organic and inorganic bases are triethylamine, pyridine, sodium hydroxide and potassium hydroxide, sodium carbonates, and the like, preferably potassium hydroxide, in a solvent to obtained compound (I) at temperature ranging from about -15 0 C to 90°C, preferably ranging from O 0 C.
  • the duration of the condensation reaction may be from 15 minutes to 5 hours depending on reagents used and measuring end point of reaction by analytical method such as TLC, HPLC and the like.
  • the suitable solvent used in Reaction B is selected from the group comprising of ethers, esters, aromatic hydrocarbon, chlorinated or non-chlorinated Aprotic solvents or mixtures thereof.
  • the ethers that can be used as solvent are selected from the group comprising of diethyl ether, tetrahydrofuran, petroleum ether (60-80 0 C.) or mixtures thereof.
  • the esters that can be used as solvent are selected from the group comprising of methyl acetate, ethyl acetate, n-butyl acetate, n-propyl acetate or mixtures thereof.
  • the aromatic hydrocarbons that can be used as solvent are selected from the group comprising of benzene, toluene, xylene or mixtures thereof.
  • Chlorinated aprotic solvents that can be used as solvent are selected from the group comprising of Chloroform, chlorobenzene, Dichloromethane, Dichloroethane, 1,1,1-trichloroethane, or any mixture thereof.
  • Non-chlorinated aprotic polar solvent that can be used as solvent are selected from the group comprising of dimethylformatnide, dimethylsulphoxide and dimethyl acetamide or any mixture thereof.
  • the solvent used in Reaction B is dichloromethane.
  • the solvent used in C can be selected from the group comprising of protic or aprotic solvents or mixtures thereof.
  • Protic solvents that can be used as solvent are selected from the group comprising of ethanol, methanol, isopropyl alcohol, and tertbutanol or any mixture thereof.
  • Aprotic solvents that can be used as solvent are selected from the group comprising of chloroform, tetrahydrofuran, and dioxane, dimethylformamide.
  • the solvent used in Reaction C is isopropyl alcohol.
  • the present invention provides a process for preparing the Lercanidipine Hydrochloride (I) as discussed herein: -
  • Reaction (B') halogenation can be carried out by using methane sulphonyl chloride, thionyl chloride, Phosphorous oxichloride, oxalylchloride, phosphorous trichloride or phosphorous pentachloride at temperature ranging from about 15°C. to 60°C preferably between 20°C. to 45 0 C, more preferably between 25°C. to 40 0 C, optionally in an inert gas atmosphere. The duration of the reaction may be from 15 minutes to 5 hours.
  • reactant used is methane sulphonyl chloride or Thionyl chloride. In a more preferred embodiment, reactant used is methane sulphonyl chloride.
  • the solvent used in reaction B' is selected from the group comprising of ethers, esters, aromatic hydrocarbon, chlorinated or non-chlorinated aprotic solvents or mixtures thereof.
  • the ethers that can be used as solvent are selected from the group comprising of diethyl ether, tetrahydrofuran, petroleum ether (60-80°C.) or mixtures thereof.
  • the esters that can be used as solvent are selected from the group comprising of methyl acetate, ethyl acetate, n-butyl acetate, n-propyl acetate or mixtures thereof.
  • the aromatic hydrocarbons that can be used as solvent are selected from the group comprising of benzene, toluene, xylene or mixtures thereof.
  • Chlorinated aprotic solvents that can be used as solvent are selected from the group comprising of chloroform, chlorobenzene, dichloromethane, dichloroethane, 1,1,1-trichloroethane, or any mixture thereof.
  • Non-chlorinated aprotic polar solvent that can be used as solvent are selected from the group comprising of dimethylformamide, dimethylsulphoxide and dimethyl acetamide or any mixture thereof.
  • the solvent used in Reaction ( B') is dichloromethane.
  • compound (I) is optionally purified in alcohol followed by treatment in ester in presence of anhydrous hydrochloric acid then the content of hydrochloric acid in ester may vary from about 0.01% w/w to about 0.5%. In a preferred embodiment it may vary from 0.05 to 0.3%. hi a more preferred embodiment it may vary from 0.05% to 0.25%.
  • Polymorphic forms can be distinguished from each other by various analytical techniques, for example, by x-ray diffraction and infrared spectroscopic techniques.
  • the present invention provides a method for preparing amorphous Lercanidipine hydrochloride comprising the steps of: (1) dissolving Lercanidipine hydrochloride in an organic solvent to prepare a solution and optionally distilled out the organic solvent (2) forming precipitates by adding an organic solvent selected from the group consisting of cyclohexane, cyclopentane, n-hexane, and ether; and (3) Isolating amorphous Lercanidipine hydrochloride
  • the organic solvent of step-1 is used to dissolve Lercanidipine hydrochloride.
  • the suitable solvent used for dissolving Lercanidipine hydrochloride are chlorohydrocarbon such as methylene chloride; alcohol such as methanol, ethanol, isopropyl alcohol and t-butyl alcohol; or a mixture of organic solvent may be used.
  • step (2) of the present invention the addition of another organic solvent may be carried out at 10°C-30°C.
  • Isolating lercanidipine hydrochloride includes filteration, washing and drying of the isolated product at appropriate condition wherein filtration should preferably be carried out after the formation of precipitates in step (2), more preferably be carried out within about 1-3 hours. Further, drying of the isolated product can be preferably carried out under vacuum at 20 ⁇ 80°C, preferably at 30 ⁇ 32°C, for 6 - 12 hours.
  • Alternative method for preparing amorphous Lercanidipine hydrochloride comprising the steps of: (1) dissolving Lercanidipine hydrochloride in alcohol such as methanol, ethanol, isopropyl alcohol and t-butyl alcohol or MDC or in a mixed organic solvent of methylene chloride and alcohol to form a solution (2) forming precipitates by adding water or by adding solution of step (1) into the water and (3) Isolating amorphous Lercanidipine hydrochloride.
  • step (2) of the alternative method the addition of water may be carried out at 10°C-30°C.
  • step (2) of the alternative method when solution is added into the water, it may optionally contain NaCl or KCl. Addition time may vary from 1 to 3 hour at 0 ⁇ 5 0 C.
  • the present invention provides still another method for preparing amorphous Lercanidipine hydrochloride comprising the steps of: (1) dissolving Lercanidipine hydrochloride in alcohol such as methanol, ethanol, isopropyl alcohol and t-butyl alcohol or MDC or in a mixed organic solvent of methylene chloride and alcohol to form a solution; (2) the solvent removed from the solution by concentrating the solution under reduced pressure or spray drying to obtain amorphous Lercanidipine hydrochloride.
  • alcohol such as methanol, ethanol, isopropyl alcohol and t-butyl alcohol or MDC
  • Lercanidipine hydrochloride (10.0 g) is dissolved in methanol (30.0 ml) with stirring for 20 minutes at 25-30 0 C. Filter the solution over hyflow bed and washed hyflow bed with methanol (20.0 ml). Distilled out methanol completely under vacuum below 40-45 0 C and kept the mass with stirring under vacuum at 40-45 0 C for 2 hours. Charge water (100.0 ml) at 25-30 0 C and stirred for 1 hour. Filtered the solution and wash the bed with 30.0 ml of water and finally dried the material under vacuum at 30-32 0 C for 12 hrs. (Dry Wt. 9.5 gm; Yield: 95%).
  • Lercanidipine hydrochloride (10.0 g) is dissolved in methanol (50.0 ml) with stirring for 20 minutes at RT. Filter the solution over hyflow bed and washed hyflow bed with methanol (20.0 ml). Distilled out methanol completely under vacuum below 40- 45°C and kept the mass with stirring under vacuum at 40-45°C for 2 hours. Charge diisopropyl ether (100.0 ml) at 25-3O 0 C and stirred for 1 hour. Filtered the solution and wash the bed with 20.0 ml of diisopropyl ether and finally dried the material under vacuum at 30-32°C for 6 hrs. (Dry Wt. 9.4 gm; Yield: 95%).
  • NaCl (2.5 g) is dissolved in water (500 ml) at 25-30 °C and cooled the solution at 0-5 °C.
  • Lercanidipine hydrochloride (20.0 g) is dissolved in methanol (35.0 ml) with stirring at 40-45 0 C. Filter the solution over hyflow bed and washed hyflow bed with methanol (5.0 ml) and add this filtrate to the NaCl solution at 0-5 °C within 1 hour. Stir the solution at 0-5 0 C for 1 hour and filter the solution over hyflow bed and washed hyflow bed with water (50.0 ml). Charge 200 ml water to the wet-cake and keep it under stirring for 30 min.
  • Lercanidipine hydrochloride (30.0 g) is dissolved in methanol (450.0 ml) with stirring for 15 minutes at 30-35 °C. Filter the solution over hyflow bed and washed hyflow bed with methanol (50.0 ml). Spray dried the material on spray drier (Input temp: 90 0 C, exhaust temp: 67 0 C, blanket nitrogen pressure: 1 kg/cm 2 , blanket nitrogen pressure: 1 kg/cm 2 ). Unload the material under nitrogen atmosphere and finally dried the material under vacuum at 30-32°C for 24 hrs. (Dry Wt. 15 gm; Yield: 50%).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to new, improved and industrially viable process for the preparation of Lercanidipine or its pharmaceutically acceptable salts using novel derivatives of 2,N-dimethyl-N-(3,3-diphenylpropyl)-l -amino compounds and novel polymorphs of Lercanidipine hydrochloride, its process of preparation.

Description

NOVEL PROCESS FOR THE PREPARATION OF LERCANIDIPINE
FIELD OF THE INVENTION:
The present invention relates to new, improved and industrially viable process for the preparation of Lercanidipine or its pharmaceutically acceptable salts using novel derivatives of 2,N-dimethyl-N-(3,3-diphenylpropyl)-l -amino compounds and novel process for the preparation of amorphous Lercanidipine hydrochloride.
BACKGROUND OF THE INVENTION:
Lercanidipine hydrochloride, i.e., 3,5-Pyridinedicarboxylic acid, l,4-dihydro-2,6- dimethyl-4-(3-nitrophenyl)-,2-[(3,3-diphenylpropyl)methylamino]- 1 , 1 -dimethyl ester, hydrochloride having the formula (I)
is an antagonist of type-L calcium channels, and has been found to be very active as an antihypertensive and is an useful agent for the treatment of angina and coronary diseases. Its mechanism of antihypertensive activity is attributed to a direct relaxant effect on vascular smooth muscle, which lowers total peripheral resistance. Lercanidipine hydrochloride (I) is disclosed in US4705797.
The preparation of said compound can be obtained with different synthetic schemes. US4705797 discloses process for the preparation of Lercanidipine Hydrochloride as described according to the following scheme: Scheme - 1
(I)
As per scheme-I crude lercanidipine is obtained as an oily residue that must be purified by flash chromatography using chloroform, containing increasing amounts of acetone, as the eluant. The solvent is then evaporated to dryness and remaining residue is dissolved in methanol adding a small excess of hydrochloric acid in ethanol. After evaporation of the solvent, the hemi-hydrated hydrochloride salt is prepared by treatment with diluted hydrochloric acid in the presence of sodium chloride.
A major disadvantage of the process of preparing lercanidipine, as it is described in US Patent No. 4705797, is that the disclosed cyclization reaction generates several by products, which result s in a lower yield for the desired product. Moreover, the purification and isolation of lercanidipine from the reaction mixture is quite complex, since it requires numerous treatments with different solvents. Finally, the purification and isolation steps are difficult to perform on an industrial scale because of the absolute necessity of purifying the product by column chromatography.
Further, US Patent No. 5912351 describes an alternate process for the preparation of lercanidipine hydrochloride. It involves reaction of 1, 4-dihydro-2, 6-dimethyl-5- methoxycarbonyl-4- (3-nitrophenyl) pyridine-3-carboxylic acid with thionyl chloride in dichloromethane and dimethylformamide at a temperature between -4° and +10 C and subsequent esterification of the obtained acid chloride with 2, N-dimethyl-N- (3, 3 diphenylpropyl)-l-arnino-2-propyl alcohol at a temperature between -10° and O0C.
However, the disadvantage of the said process is the use of thionyl chloride as a reactant, which is difficult to handle on an industrial scale because of evolution of sulphur dioxide and hydrochloric gas from the reaction. Moreover it also requires special grade of equipment such as glass-lined reactor etc.
Thus, there is a demand for a simpler, cost-effective, industrially viable process for synthesizing Lercanidipine with higher yields, while reducing number of process steps and avoiding use of harmful reagents, solvents and laborious separation methods such as column chromatography.
The Applicant has found simpler and cost-effective process for synthesizing Lercanidipine, avoiding use of hazardous materials, which is industrially viable and gives better yields.
Further WO/03/014084 discloses novel crystalline form I & II of Lercanidipine Hydrochloride and mixtures of Form I & II having predetermined and reproducible content of Form I & II & optionally other forms of Lercanidipine Hydrochloride such as amorphous. EP 1600441 discloses crystalline form I of Lercanidipine Hydrochloride and a mixture of form I with amorphous and optionally form II. However, these prior art don't describe pure amorphous form (anhydrous or hemihydrate) of Lercanidipine Hydrochloride and its preparation.
Further, WO2006089787A1 discloses process for the preparation of pure amorphous lercanidipine hydrochloride from crystalline lercanidipine hydrochloride.
Thus, the present invention provides obvious benefits with respect to removing both the technical problems associated with prior art as well being simpler and economical, while at the same time achieving high purity and yield of the product with convenience to operate on a commercial scale.
SUMMARY OF THE INVENTION:
The present invention relates to new, improved and industrially viable process for the preparation of Lercanidipine hydrochloride using novel intermediate of amino phenyl derivatives of formula (III) with 1,4-dihydropyridine acid derivative.
( III )
Wherein R is X OrOSO2R
X = Cl, F, Br or I ; R = alkyl (C1 to C 4) , phenyl, or 4-methyl phenyl.
OBJECTS OF THE INVENTION
The object of the present invention is to provide a new and improved process for synthesis of Lercanidipine hydrochloride. The second object of the instant invention is to provide a simpler and cost-effective process for synthesis of Lercanidipine hydrochloride.
Another object of the present invention is to provide an industrially viable process for synthesis of Lercanidipine hydrochloride.
Still another object of the present invention is to provide an improved process for synthesis of Lercanidipine hydrochloride, which gives better yield.
Yet another object of the present invention is to provide novel polymorphic forms of Lercanidipine hydrochloride and process for the preparation thereof.
Yet another object of the present invention is to provide novel process for amorphous form of Lercanidipine hydrochloride.
In one general embodiment, the present invention provides a process for the preparation of lercanidipine hydrochloride of formula (I) as described herein below:
Which comprises the steps of:
1) Halogenation of 2,N-Dimethyl-N-(3,3-diphenyl propyl)- l-amino-2- propanol (II)
( M ) in an suitable solvent optionally in presence of a base to obtain derivatives of 2,N- Dimethyl-N-(3,3-diphenyl propyl)-! -amino (III)
2) Reacting 2,6-dimethyl-5-methoxy carbonyl-4-(3-nitrophenyl)-l,4- dihydropyridine-3-carboxylic acid of formula (IV)
in a protic or aprotic solvent with formula III in presence of base; and
3) Isolating resultant lercanidipine or its Pharmaceutically acceptable salts
BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS:
Fig. 1: This figure indicates X-ray diffraction pattern of amorphous Form Tl of Lercanidipine hydrochloride obtained according to the present invention.
Fig. 2: This figure indicates Infrared Spectrum of amorphous Form Tl Lercanidipine hydrochloride obtained according to the present invention.
Fig. 3: This figure indicates Differential Scaning Calorimetry of amorphous Form Tl Lercanidipine hydrochloride obtained according to the present invention. DETAILED DESCRIPTION:
According to one general aspect of the present invention, there is provided a new, improved and industrially viable process for the preparation of Lercanidipine Hydrochloride, using novel intermediate of amino phenyl compounds of formula III with 1,4-dihydropyridine acid derivative of formula (IV).
According to one aspect of the present invention, there is provided an efficient process for the preparation of Lercanidipine, which provides obvious benefits with respect to economics, generation of minimal effluents, lesser number of process steps, less reactor occupancy, higher purity of the product with convenience to operate on a commercial scale.
According to one another aspect of the present invention there is provided a new, improved and industrially viable process for the preparation of Lercanidipine Hydrochloride, using a novel intermediate of 2-halo amino derivative of formula (III) wherein R=X, with or without insitu formation of Sulphonic acid ester of amino alcohol of formula (III).
The present invention provides an improved process for preparing Lercanidipine Hydrochloride (I) as discussed herein: -
The process of the invention is illustrated by the following reaction scheme.
Reaction-(A)
The 2,N-Dimethyl-N-(3,3-diphenyl propyl)- l-amino-2-propanol Formula ( II ) is prepared according to a procedure known in the prior art (US 4705797)
Reaction-(A)
Reaction-(B)
A process comprising the halogenation of compound of Formula (II) to obtain compound of formula (IIIB), characterized in that:
(a) Reacting 2,N-Dimethyl-N-(3,3-diphenyl propyl)- l-amino-2-propanol Formula ( II ) with Alkyl or aryl or substituted aryl sulphonyl halide in presence of base in suitable solvent or mixture thereof to obtained, compound of formula ( IIIB) via insitu formation of Sulphonic acid ester of N-Dimethyl-N- (3,3-diphenyl propyl)-l- amino-2-propanol compound (IIIA), Wherein R' = alkyl (C1-4), phenyl, p-tolyl and X = Cl, Br, F, or I or.
( HIB )
Reaction B -(a) (a') Reacting 2,N-Dimethyl-N-(3,3-diphenyl propyl)-l-amino-2-propanol Formula ( II ) with Halogenating agent in suitable solvent or mixture thereof to obtained, of N- Dimethyl-N- (3,3-diphenyl propyl)- l-amino-2-halide compound (IHB) Wherein X = Cl, Br, F, or I. In a preferred embodiment X = chloride, R" = thionyl chloride, Phosphorous oxychloride, Oxaloylchloride, phosphorous trichloride or phosphorous pentachloride.
Reaction B -(a1)
Reaction-(C): Reacting 2,6-dimethyl-5-methoxy carbonyl-4- (3-nitrophenyl)-l,4- dihydropyridine-3-carboxylic acid of formula (IV)
( I ) Reaction - (C) with halide compound of N-Dimethyl-N-(3,3-diphenyl propyl)- 1 -amino compound ( IIIB ) in presence of base in protic or aprotic solvent mixtures thereof to obtained compound ( I ) optionally purifying the product in alcohol alone or followed by the treatment of the isolated product/residue in a solvent such as ester containing anhydrous Hydrochloric acid.
Reaction B-(a) can be carried out using by methane sulphonyl halide, p-toluene sulphonyl chloride, or benzene sulphonyl chloride using base selected from the group comprising of organic base, inorganic bases. Examples of organic and inorganic bases are triethylamine, pyridine, sodium hydroxide and potassium hydroxide, sodium carbonates, and the like, at temperature ranging from about -15°C. to 60°C, preferably between -5°C. to 250C, more preferably between 5°C. to 2O0C, optionally in an inert gas atmosphere. The duration of the esterification reaction may be from 15 minutes to 5 hours depending on reagents used and measuring end point of reaction by analytical method such as TLC, HPLC and the like.
Reaction B-(a') can be carried out by using thionyl chloride, Phosphorous oxichloride, oxalylchloride, phosphorous trichloride or phosphorous pentachloride at temperature ranging from about 150C. to 60°C, preferably between 2O0C. to 45°C, more preferably between 250C. to 40°C, optionally in an inert gas atmosphere. The duration of the reaction may be from 15 minutes to 5 hours.
Surprisingly inventor have found that use of methane sulphonyl chloride generates mesylate ester insitu as described herein, but ultimately leads to formation of chloro derivative (Formula HI(B)) instead of mesyl ester of formula III (A) as described herein. The structure elucidation of isolated chloro derivative is supported by the analytical techniques.
Reaction (C) as per the present invention can be carried out using in general by reacting compound (IIIB) with 2,6-dimethyl-5-methoxy carbonyl-4-(3-nitrophenyl)- l,4-dihydropyridine-3-carboxylic acid of formula (IV) using base selected from the group comprising of organic base, inorganic bases. Examples of organic and inorganic bases are triethylamine, pyridine, sodium hydroxide and potassium hydroxide, sodium carbonates, and the like, preferably potassium hydroxide, in a solvent to obtained compound (I) at temperature ranging from about -150C to 90°C, preferably ranging from O0C. to 400C, more preferably ranging from 25°C to 300C optionally in an inert gas atmosphere. The duration of the condensation reaction may be from 15 minutes to 5 hours depending on reagents used and measuring end point of reaction by analytical method such as TLC, HPLC and the like.
The suitable solvent used in Reaction B is selected from the group comprising of ethers, esters, aromatic hydrocarbon, chlorinated or non-chlorinated Aprotic solvents or mixtures thereof. The ethers that can be used as solvent are selected from the group comprising of diethyl ether, tetrahydrofuran, petroleum ether (60-800C.) or mixtures thereof. The esters that can be used as solvent are selected from the group comprising of methyl acetate, ethyl acetate, n-butyl acetate, n-propyl acetate or mixtures thereof. The aromatic hydrocarbons that can be used as solvent are selected from the group comprising of benzene, toluene, xylene or mixtures thereof. Chlorinated aprotic solvents that can be used as solvent are selected from the group comprising of Chloroform, chlorobenzene, Dichloromethane, Dichloroethane, 1,1,1-trichloroethane, or any mixture thereof. Non-chlorinated aprotic polar solvent that can be used as solvent are selected from the group comprising of dimethylformatnide, dimethylsulphoxide and dimethyl acetamide or any mixture thereof.
In a preferred embodiment, the solvent used in Reaction B is dichloromethane.
The solvent used in C can be selected from the group comprising of protic or aprotic solvents or mixtures thereof. Protic solvents that can be used as solvent are selected from the group comprising of ethanol, methanol, isopropyl alcohol, and tertbutanol or any mixture thereof. Aprotic solvents that can be used as solvent are selected from the group comprising of chloroform, tetrahydrofuran, and dioxane, dimethylformamide.
In a preferred embodiment, the solvent used in Reaction C is isopropyl alcohol.
In an alternative embodiment, the present invention provides a process for preparing the Lercanidipine Hydrochloride (I) as discussed herein: -
The process of the invention is illustrated by the following reaction scheme.
Reaction-(A)
The 2,N-Dimethyl-N-(3,3-diphenyl propyl)- l-amino-2-propanol Formula( II ) is prepared according to a procedure known in the prior art (US 4705797)
Reaction - (A) Reaction-(B')
Reacting 2,N-Dimethyl-N-(3,3-diphenyl propyl)- l-amino-2-propanol Formula ( II )
( I ) Reaction -(B) with halogenating agent in suitable solvent and then reacting insitu the halogenated compound so obtained with 2,6-dimethyl-5-methoxy carbonyl-4- (3-nitrophenyl)- l,4-dihydropyridine-3-carboxylic acid of formula (IV) without isolation of formula IH(B) to obtained compound (I), optionally purifying the product in alcohol alone or followed by the treatment of the isolated product/residue in a solvent such as ester containing anhydrous Hydrochloric acid. .
In Reaction (B') halogenation can be carried out by using methane sulphonyl chloride, thionyl chloride, Phosphorous oxichloride, oxalylchloride, phosphorous trichloride or phosphorous pentachloride at temperature ranging from about 15°C. to 60°C preferably between 20°C. to 450C, more preferably between 25°C. to 400C, optionally in an inert gas atmosphere. The duration of the reaction may be from 15 minutes to 5 hours. hi a preferred embodiment, reactant used is methane sulphonyl chloride or Thionyl chloride. In a more preferred embodiment, reactant used is methane sulphonyl chloride.
The solvent used in reaction B' is selected from the group comprising of ethers, esters, aromatic hydrocarbon, chlorinated or non-chlorinated aprotic solvents or mixtures thereof. The ethers that can be used as solvent are selected from the group comprising of diethyl ether, tetrahydrofuran, petroleum ether (60-80°C.) or mixtures thereof. The esters that can be used as solvent are selected from the group comprising of methyl acetate, ethyl acetate, n-butyl acetate, n-propyl acetate or mixtures thereof. The aromatic hydrocarbons that can be used as solvent are selected from the group comprising of benzene, toluene, xylene or mixtures thereof. Chlorinated aprotic solvents that can be used as solvent are selected from the group comprising of chloroform, chlorobenzene, dichloromethane, dichloroethane, 1,1,1-trichloroethane, or any mixture thereof. Non-chlorinated aprotic polar solvent that can be used as solvent are selected from the group comprising of dimethylformamide, dimethylsulphoxide and dimethyl acetamide or any mixture thereof.
In a preferred embodiment, the solvent used in Reaction ( B') is dichloromethane. When compound (I) is optionally purified in alcohol followed by treatment in ester in presence of anhydrous hydrochloric acid then the content of hydrochloric acid in ester may vary from about 0.01% w/w to about 0.5%. In a preferred embodiment it may vary from 0.05 to 0.3%. hi a more preferred embodiment it may vary from 0.05% to 0.25%.
In yet another aspect of the present invention there is provided a novel polymorphic form Tl of Lercanidipine hydrochloride e.g. amorphous form.
Due to differing solubility profiles of polymorphs, the identification of pharmaceutical polymorphs is essential for preparing pharmaceutical dosage forms with predictable solubility profiles. Polymorphic forms can be distinguished from each other by various analytical techniques, for example, by x-ray diffraction and infrared spectroscopic techniques.
Among the known polymorph of Lercanidipine Hydrochloride the solubility and thereby its bioavailability is very less. Hence, in an another embodiment of the invention there is provided new amorphous form Tl of Lercanidipine hydrochloride and process of preparation thereof.
In another aspect, the present invention provides a method for preparing amorphous Lercanidipine hydrochloride comprising the steps of: (1) dissolving Lercanidipine hydrochloride in an organic solvent to prepare a solution and optionally distilled out the organic solvent (2) forming precipitates by adding an organic solvent selected from the group consisting of cyclohexane, cyclopentane, n-hexane, and ether; and (3) Isolating amorphous Lercanidipine hydrochloride
The organic solvent of step-1 is used to dissolve Lercanidipine hydrochloride. The suitable solvent used for dissolving Lercanidipine hydrochloride are chlorohydrocarbon such as methylene chloride; alcohol such as methanol, ethanol, isopropyl alcohol and t-butyl alcohol; or a mixture of organic solvent may be used.
In step (2) of the present invention, the addition of another organic solvent may be carried out at 10°C-30°C.
Isolating lercanidipine hydrochloride includes filteration, washing and drying of the isolated product at appropriate condition wherein filtration should preferably be carried out after the formation of precipitates in step (2), more preferably be carried out within about 1-3 hours. Further, drying of the isolated product can be preferably carried out under vacuum at 20 ~ 80°C, preferably at 30 ~ 32°C, for 6 - 12 hours.
Alternative method for preparing amorphous Lercanidipine hydrochloride comprising the steps of: (1) dissolving Lercanidipine hydrochloride in alcohol such as methanol, ethanol, isopropyl alcohol and t-butyl alcohol or MDC or in a mixed organic solvent of methylene chloride and alcohol to form a solution (2) forming precipitates by adding water or by adding solution of step (1) into the water and (3) Isolating amorphous Lercanidipine hydrochloride.
In step (2) of the alternative method, the addition of water may be carried out at 10°C-30°C.
In step (2) of the alternative method, when solution is added into the water, it may optionally contain NaCl or KCl. Addition time may vary from 1 to 3 hour at 0 ~ 5 0C. The present invention provides still another method for preparing amorphous Lercanidipine hydrochloride comprising the steps of: (1) dissolving Lercanidipine hydrochloride in alcohol such as methanol, ethanol, isopropyl alcohol and t-butyl alcohol or MDC or in a mixed organic solvent of methylene chloride and alcohol to form a solution; (2) the solvent removed from the solution by concentrating the solution under reduced pressure or spray drying to obtain amorphous Lercanidipine hydrochloride.
Method and condition of the measurement of X-ray diffraction patterns.
(1) Method of the measurement
X-ray diffraction patterns were measured on each 400 mg of the sample of Lercanidipine hydrochloride by the following condition.
(2) Condition of measurement
While the present invention has been described in term of its specific embodiments, certain modifications & equivalents will be apparent to scope of the instant invention.
In the following section, embodiments are described by way of examples to illustrate the process of invention; however this does not limit the scope of the present invention. Several variants of these examples would be evident to person's skill in the art. PREPARATORY EXAMPLES:
Example -1
Preparation of N-(2-chloro-2-methyIpropyI)-N-(3,3-diphenylpropyl)-N- methylamine.
To a solution of lOOgms of 2,N -Dimethyl-N-(3,3-diphenyl propyl)- l-amino-2- propanol(II), 1.3L of dichloromethane, 44gms of triethyl amine, add solution of Methane sulphonyl chloride in dichloromethane (42.4gm. in 0.2L) at 20°-25°C. in 2- 2.5hrs. .Stir the reaction mass at 20°- 25°C for 4 hours. Check the content of 2,N- Dimethyl-N-(3,3-Diphenylpropyl)-l-Amino-2-Propanol by HPLC. Charge water at 20°-25°C and stir for 20 minutes and separate layers. Wash the Dichloromethane layer with 5 % aq. sodium bicarbonate solution (1.0 L) , water (l.OL) at 25-30°C respectively. Take Dichloromethane layer and charge Na2SO4(10gm) at 25-30°C. Filter the solution through cotton cloth and wash the bed with Dichloromethane. Remove the excess solvent (Dichloromethane) under vacuum below 30°C to give a heavy oil of N-(2-chloro-2-methylpropyl)-N-(3,3-diphenylpropyl)-N-methylamine (Yield: lOOgms; 94%)
IH NMR: 7.330-7.397(8H, m); 7.225-7.284(2H, m); 4.054(1H, t); 2.647(2H, s); 2.548(2H, t); 2.293-2.350(2H, q); 2.462(3H, s); 1.577(6H, s) IR: 1492.8, 1451.3 (Ar.C=C), 1107.1 (C-N stretching), 700.1 (C-Cl stretching) Elemental analysis: Carbon - 75.02%, Nitrogen - 4.07%, Hydrogen - 8.39%
Example - 2
Preparation of 3,5-Pyridinedicarboxylic acid, l,4-dihydro-2,6-dimethyI-4-(3~ nitrophenyl)-,2-[(3,3-diphenylpropyI)methylamino]-l,l-dimethyl ester, hydrochloride [ Lercanidipine hydrochloride) ] (I)
To a stirred solution of 80 gm of 2,6-Dimethyl-5-methoxy carbonyl-4-(3- Nitrophenyl)-l,4-dihydropyridine-3-carboxylicacid, Isopropyl alcohol (0.8L), 20gm of powdered potassium hydroxide, charge solution of N-(2-chloro-2-methylpropyl)- N-(3,3-diphenylpropyl)-N-methylamine in Isopropyl alcohol (lOOgms in 0.2L IPA) under stirring. Stir the reaction mass at 25°-30°C. for 3 hrs. Check the absence of N- (2-Chloro-2-methylpropyl)-N-(3,3-diphenylpropyl)-N-methylamine by TLC. Distill out Isopropyl alcohol completely under vacuum below 50°C. Charge ethyl acetate (2.0L) & Water (1.0L). Stir for 30 min. & separate the layers. Wash the ethyl acetate layer with 1.5 L of 10% Na2CO3 solution in three parts at 25°-30°C followed by washing of organic layer charge with brine solution(0.5L) and 1.5 L of 10% HCL in three separate parts followed by brine solution (0.5L) and finally treatment of NaSO4(20gm) to an organic layer. Filter the solution over cotton cloth and wash the bed with ethylacetate( 0.05 L). Charge 0.01 kg of activated charcoal at 25-30°C. Stir at 25-30°C for 30.0 min. Filter the solution over hyflow bed (0.020 kg of hyflow slurry in 0.150 L of ethylacetate) Distill out ethyl acetate under vacuum below 500C. Charge ethylacetate (l.OL) to the reaction mass at 5O-55°C and stir at 50-55°C for 30 mins. Cool to 25°-30°C and seed the reaction mass with Lercanidipine Hydrochloride crystals. Stir for 16hrs. at 25°-30°C. Filter the reaction mass and wash the cake with Ethylacetate(0.02L). Suck dried and stir the wet material in ethylacetate (0.8L) for 30.0 min. and filter the material. Wash the bed with Ethylacetate (0.02L). Suck dried for 1 hr and dry the material under vaccum at 30-35°C for 8 hrs till constant weight is attained. (Yield: 95 gm; 47%)
Example - 3
Preparation of 3,5-Pyridinedicarboxylic acid, l,4-dihydro-2,6-dimethyl-4-(3- nitrophenyl)-,2-[(3,3-diphenylpropyl)methylamino]-l,l-dimethyl ester, hydrochloride [ Lercanidipine hydrochloride) ] (I)
To a stirred solution of 80 gm of 2,6-Dimethyl-5-methoxy carbonyl-4-(3- Nitrophenyl)-l,4-dihydropyridine-3-carboxylicacid, Isopropyl alcohol (0.8L), 20gm of powdered potassium hydroxide, charge solution of N-(2-chloro-2-methylpropyl)- N-(3,3-diphenylpropyl)-N-methylamine in Isopropyl alcohol (lOOgms in 0.2L IPA) under stirring. Stir the reaction mass at 25°-30°C. for 3 hrs. Check the absence of N- (2-Chloro-2-methylpropyl)-N-(3,3-diphenylpropyl)-N-methylamine by TLC. Distill out Isopropyl alcohol completely under vacuum below 50°C. Charge ethyl acetate (2.0L) & Water (LOL). Stir for 30 min. & separate the layers. Wash the ethyl acetate layer with 1.5 L of 10% Na2CO3 solution followed by washing of organic layer with brine solution(0.5L) and finally treatment of NaSO4(20gm) to an organic layer. Decant the ethylacetate layer and cool the mass to 20°-25°C. Add anhydrous hydrochloric acid in ethyl acetate to adjust the pH of the mass below 2.0 and seed the reaction mass with Lercanidipine Hydrochloride. Stir the reaction mass for 16hrs. at 20°-25°C. Filter the reaction mass and wash the cake with Ethylacetate(0.02L). Suck dried and stir the wet material in ethylacetate (0.8L) for 30.0 min. and filter the material. Wash the bed with Ethylacetate (0.02L). Suck dried for 1 hr and dry the material under vaccum at 30-350C for 8 hrs till constant weight is attained. (Yield: 96 gm; 47%)
Example -4
Purification of crude lercanidipine hydrochloride
Charge Crude Lercanidipine hydrochloride (0.1 Kg) and Absolute Ethanol (0.3L) at 25-30°C. Heat to 75-80 ° C in 20.0 min. and Stir at 75-80 ° C for 5.0 min to get clear solution. Filter the solution over hyflow bed (0.01 Kg hyflow slurry prepared in 0.02 It of absolute Ethanol) and Wash with absolute Ethanol (0.025 L). Cool to 25- 3O0C and seed with Lercanidipine hydrochloride (0.0002 Kg) obtained in example 2 above and stir at 25-300C for 16 hrs. Filter the material and wash the bed with Chilled absolute Ethanol (0.025 L, 0-50C) and Suck dry the material for 1 hr. Take the wet material and charge absolute Ethanol (0.3 L) at 25-3O0C and Heat up to 75-80° C in 20.0 min. Stir at 75-80° C for 5.0 min to get clear solution. Filter the solution over hyflow bed (0.01 Kg hyflow slurry prepared in 0.02 It of absolute Ethanol). Wash the bed with absolute Ethanol (0.025 L) and Cool to 25-300C and seed with Lercanidipine hydrochloride (0.0002 Kg). Stir at 25-300C for 16 hrs. and Filter the material and wash the bed with Chilled absolute Ethanol ( 0.025 L, 0-50C). Suck dry the material for 1 hr and dry the material in vacuum oven under vacuum at 30- 350C for 8 hrs to get Ethanol below 3000 ppm by residual solvent test. HPLC Purity: ~ 99.9 % Yield: 75 gm (75%)
Example -5
Purification of crude lercanidipine hydrochloride
Charge Crude Lercanidipine hydrochloride (17g) obtained from example 2 in methanol(0.05L) at 25-300C. Heat to 35-40 ° C to get clear solution. Filter the solution over hyflow bed . Distill out the methanol filterate under vacuum. Charge ethyl acetate (0.170L) and anhydrous hydrochloric acid (0.005L; 9.5%w/w in ethylacetate).Stir at 25-30 ° C for five hours. Filter the reaction mass and wash the solid with ethylacetate. HPLC Purity: ~ 99.9 % Yield: 14 gm (-82.4%)
Example -6
Preparation of N-(2-chIoro-2-methylpropyl)-N-(3,3-diphenylpropyl)-N- methylamine (HIB)
To a solution of 3.5gm of 2,N -Dimethyl-N-(3,3-diphenyl propyl)- l-amino-2- propanol(H), prepared as described in US Patent 4705797, is reacted with thionyl chloride in presence of methylenechloride for 5 hrs. at reflux tempearature to get N- (2-chloro-2-methylpropyl)-N-(3,3-diphenylpropyl)-N-methylamine (8.5 gm) (Yield: Example - 7
Preparation of 3,5-PyridinedicarboxyIic acid, l,4-dihydro-2,6-dimethyI-4-(3- nitrophenyl)-,2-[(3,3-diphenylpropyI)methylamino]-l,l-dimethyI ester, hydrochloride [ Lercanidipine hydrochloride) ] (I)
N-(2-chloro-2-methylpropyl)-N-(3,3-diphenylpropyl)-N-methylamine (IIIB)(8.5gm) is reacted with 2,6-Dimethyl-5-methoxy carbonyl-4-(3-Nitrophenyl)-l,4- dihydropyridine-3-carboxylicacid in presence of triethylamine and isopropyl alcohol at 30° to 35° for 2 hr to get Lercanidipine Hydrochloride (8.0gm). (Yield: 47.3%)
Example — 8
Preparation of Amorphous Form of Lercanidipine Hydrochloride
Charge Lercanidipine hydrochloride (10.0 g) in Methanol (30.0 ml) at 25-30°C. and stir for 15.0 min to get clear solution. Filter the solution over hyflow bed(5.0 g of Hyflow is prepared in 30.0 ml of Methanol). Distill out Methanol completely under vacuum at 40-45°C and keep the mass under vacuum at 40-450C for 30.0 min. Charge n-Hexane (50.0 ml) at 25-30°C. and stir for 30.0 min. Filter the solution and wash the bed with 20.0 ml of n-Hexane and finally dry the material under vacuum below 35°C for 8 hrs . (Dry Wt. 9.5 gm; Yield: 95%)
Example -9
Preparation of N-(2-chloro-2-methylpropyl)-N-(3,3-diphenylpropyl)-N- methylamine.
To a solution of lOOgms of 2,N -Dimethyl-N-(3,3-diphenyl propyl)- l-amino-2- propanol(II), 1.3L of dichloromethane, 44.2gms of triethyl amine and cool it to 20-25 °C, add solution of Methane sulphonyl chloride in dichloromethane (46.2gm. in 0.2L) at 20°-25°C in 3-3.5 hrs. .Stir the reaction mass at 20°- 25°C for 4 hours. Check the content of 2,N-Dimethyl-N-(3,3-Diphenylpropyl)-l-Amino-2-Propanol by HPLC. Charge 1.0L water at 20°-25°C and stir for 20 minutes and separate layers. Wash the Dichloromethane layer with 5 % aq. sodium bicarbonate solution (1.0 L) , water (LOL) at 25-3O0C respectively. Take Dichloromethane layer and charge Na2SO4 (10gm) at 25-3O0C. Filter the solution through cotton cloth and wash the bed with Dichloromethane. Remove the excess solvent (Dichloromethane) under vacuum below 3O0C to obtain a heavy oil of N-(2-chloro-2-methylpropyl)-N-(3,3- diphenylpropyl)-N-methylamine (Yield: 102gms; 95.8%).
Example - 10
Preparation of 3,5-Pyridinedicarboxylic acid, l,4-dihydro-2,6-dimethyl-4-(3- nitrophenyl)-,2-[(3,3-diphenylpropyl)methylamino]-l,l-dimethyl ester, hydrochloride [ Lercanidipine hydrochloride) ] (I)
To a stirred solution of 80 gm of 2,6-Dimethyl-5-methoxy carbonyl-4-(3- Nitrophenyl)-l,4-dihydropyridine-3-carboxylicacid, Isopropyl alcohol (0.4L), 20gm of powdered potassium hydroxide, charge solution of N-(2-chloro-2-methylpropyl)- N-(3,3-diphenylpropyl)-N-methylamine in Isopropyl alcohol (lOOgms in 0.2L IPA) under stirring. Stir the reaction mass at 25°-30°C for 5 hrs. Check TLC for the absence of N-(2-Chloro-2-methylpropyl)-N-(3,3-diphenylpropyl)-N-methylamine. Distill out Isopropyl alcohol completely under vacuum below 55°C. Charge ethyl acetate (2.0L) at 45-55 °C and stir for 15 min at 45-55 0C to get clear solution and cool it to 25-30 °C. Then add water (1.0 L) at 25-30 °C & separate the layers. Wash the ethyl acetate layer with 1.0 L of 5.0% Na2CO3 solution and stir at 25°-30°C for 30 min. and separate the layers. Take the ethyl acetate layer & add water (1.0 L) and stir at 25°-30°C for 30 min. and separate the layers. Followed by washing of organic layer with 0.5 L of 10% HCL and stir at 25°-30°C for 30 min and separate the layers. Take the ethyl acetate layer & add 0.5 L of 10% HCL and stir at 25°-30°C for 30 min. and separate the layers. Followed by treatment with brine solution (0.5L, 25%) and finally treatment of NaSO4 (lOOgm) to an organic layer. Filter the solution over cotton cloth and wash the bed with ethylacetate( 0.2 L). Take ethyl acetate layer and charge 0.01 kg of activated charcoal at 25-3O0C & stir at 25-30°C for 30.0 min. Filter the solution over hyflow bed and wash the bed with ethyl acetate (0.05 L). Distill out ethyl acetate under vacuum below 55 °C & again charge 200 ml ethyl acetate and distill out ethyl acetate completely under vacuum below 55 0C. Charge ethyl acetate (1.0L) to the reaction mass at 50-55°C and stir at 50-550C for 30 mins. Cool it to 25°- 300C and seed the reaction mass with Lercanidipine Hydrochloride crystals. Stir for 24 hrs. at 25°-30°C. Filter the reaction mass and wash the cake with Ethyl acetate (0.1 L) and dry the material under vacuum at 40-450C for 8 hrs. (Yield: 105 gm; 51.94%)
Example - 11
Preparation of Amorphous Form of Lercanidipine Hydrochloride
Lercanidipine hydrochloride (10.0 g) is dissolved in methanol (30.0 ml) with stirring for 20 minutes at 25-300C. Filter the solution over hyflow bed and washed hyflow bed with methanol (20.0 ml). Distilled out methanol completely under vacuum below 40-450C and kept the mass with stirring under vacuum at 40-450C for 2 hours. Charge water (100.0 ml) at 25-300C and stirred for 1 hour. Filtered the solution and wash the bed with 30.0 ml of water and finally dried the material under vacuum at 30-320C for 12 hrs. (Dry Wt. 9.5 gm; Yield: 95%).
Example - 12
Preparation of Amorphous Form of Lercanidipine Hydrochloride
Lercanidipine hydrochloride (10.0 g) is dissolved in methanol (50.0 ml) with stirring for 20 minutes at RT. Filter the solution over hyflow bed and washed hyflow bed with methanol (20.0 ml). Distilled out methanol completely under vacuum below 40- 45°C and kept the mass with stirring under vacuum at 40-45°C for 2 hours. Charge diisopropyl ether (100.0 ml) at 25-3O0C and stirred for 1 hour. Filtered the solution and wash the bed with 20.0 ml of diisopropyl ether and finally dried the material under vacuum at 30-32°C for 6 hrs. (Dry Wt. 9.4 gm; Yield: 95%).
Example - 13
Preparation of Amorphous Form of Lercanidipine Hydrochloride
NaCl (2.5 g) is dissolved in water (500 ml) at 25-30 °C and cooled the solution at 0-5 °C. Lercanidipine hydrochloride (20.0 g) is dissolved in methanol (35.0 ml) with stirring at 40-45 0C. Filter the solution over hyflow bed and washed hyflow bed with methanol (5.0 ml) and add this filtrate to the NaCl solution at 0-5 °C within 1 hour. Stir the solution at 0-5 0C for 1 hour and filter the solution over hyflow bed and washed hyflow bed with water (50.0 ml). Charge 200 ml water to the wet-cake and keep it under stirring for 30 min. at 25-30 °C and filter the solution over hyflow bed and washed hyflow bed with water (50.0 ml). Finally dried the material under vacuum at 30-32°C for 12 hrs. (Dry Wt. 19 gm; Yield: 95%).
Example — 14
Preparation of Amorphous Form of Lercanidipine Hydrochloride
Lercanidipine hydrochloride (10.0 g) is dissolved in methanol (50.0 ml) with stirring for 20 minutes at RT. Filter the solution over hyflow bed and washed hyflow bed with methanol (20.0 ml). Distilled out methanol completely under vacuum below 40- 45°C and kept the mass with stirring under vacuum at 40-450C for 8 hours. Dried material is taken out from the flask and finally dried the material under vacuum at 30- 32°C for 6 hrs. Example - 15
Preparation of Amorphous Form of Lercanidipine Hydrochloride
Lercanidipine hydrochloride (30.0 g) is dissolved in methanol (450.0 ml) with stirring for 15 minutes at 30-35 °C. Filter the solution over hyflow bed and washed hyflow bed with methanol (50.0 ml). Spray dried the material on spray drier (Input temp: 90 0C, exhaust temp: 67 0C, blanket nitrogen pressure: 1 kg/cm2, blanket nitrogen pressure: 1 kg/cm2). Unload the material under nitrogen atmosphere and finally dried the material under vacuum at 30-32°C for 24 hrs. (Dry Wt. 15 gm; Yield: 50%).

Claims

We Claim:
1. A process for the preparation of Lercanidipine of formula (I) or a pharmaceutically acceptable salt thereof,
comprising: a) Halogenating 2,N-Dimethyl-N-(3,3-diphenyl propyl)- l-amino-2-propanol (II)
in a suitable solvent or mixture thereof, optionally in the presence of base to obtain derivatives of 2,N-Dimethyl-N-(3,3-diphenyl propyl)- 1 -amino (UIB)
Wherein X= Cl, F, Br or I b) Reacting 2,6-dimethyl-5 -methoxy carbonyl-4-(3 -nitrophenyl)- 1 ,4- dihydropyridine-3-carboxylic acid of formula (IV)
( IV )
in a protic or aprotic solvent with compound of formula IIIB in presence of base and c) optionally converting into its pharmaceutically acceptable salt.
2. The process according to claim 1, wherein the halogenating agent is methane sulphonyl halide, P-toluene sulphonyl chloride, benzene sulphonyl chloride, thionyl chloride, phosphorous oxychloride, oxalylchloride, phosphorous trichloride or phosphorous pentachloride.
3. The process according to claim 1, wherein suitable solvent used in step a is selected from the group comprising of ethers, ester, aromatic hydrocarbon, chlorinated or nor chlorinated aprotic solvents or mixture thereof.
4. The process according to claim 1, wherein protic or aprotic solvent used in step b is selected from the group comprising of alcohol, chloroform, THF, dioxane and DMF.
5. Amino phenyl derivative of the following formula (III B):
wherein, X = Cl, F, Br or I, or salts thereof.
6. Use of the compound of claim 5 for the manufacture of Lercanidipine or pharmaceutically acceptable salts thereof.
7. Novel amorphous form Tl of Lercanidipine Hydrochloride.
8. The amorphous form according to claim 7, characterized by an X-ray powder diffraction pattern substantially in accordance with Fig-1.
9. A process for the preparation of amorphous Lercanidipine hydrochloride comprising the steps of:
i) dissolving Lercanidipine hydrochloride in an organic solvent selected from alcohol or MDC or in a mixed organic solvent of methylene chloride and alcohol to prepare a solution and optionally distilled out the organic solvent;
ii) a) forming precipitates by adding water or by adding solution of step (i) into the water ; or b) forming precipitate by adding an organic solvent selected from cyclohexane cyclopentane, n-hexane or ether ; or c) the solvent removed from the solution of step (i) by concentrating the solution under reduced pressure or, d) spray drying to obtain a solid substance;
iii) Isolating lercanidipine hydrochloride
10. Process for the preparation of lercanidipine hydrochloride and its amorphous form s herein described, particularly with reference to the foregoing examples.
EP06842760A 2005-09-21 2006-09-19 Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride Withdrawn EP1963254A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1164MU2005 2005-09-21
IN1593MU2005 2005-12-19
PCT/IN2006/000376 WO2007054969A2 (en) 2005-09-21 2006-09-19 Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride

Publications (1)

Publication Number Publication Date
EP1963254A2 true EP1963254A2 (en) 2008-09-03

Family

ID=38023682

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06842760A Withdrawn EP1963254A2 (en) 2005-09-21 2006-09-19 Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride

Country Status (2)

Country Link
EP (1) EP1963254A2 (en)
WO (1) WO2007054969A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR052918A1 (en) 2005-02-25 2007-04-11 Recordati Ireland Ltd LERCANIDIPINE AMORFO CHLORHYDRATE
PL2164349T3 (en) 2006-08-04 2015-03-31 Shs Int Ltd Protein free formula
KR100928995B1 (en) * 2007-10-31 2009-11-26 (주)에이에스텍 Amorphous anhydrous lercanidipine and its improved preparation
CA2784131C (en) 2009-12-16 2017-07-11 Hetero Research Foundation Polymorphs of darunavir
US8853430B2 (en) 2010-05-20 2014-10-07 Hetero Research Foundation Crystalline hydrochloride salt of darunavir
EP2444394A1 (en) * 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Process for the preparation of amorphous form of lercanidipine HCI

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007054969A3 *

Also Published As

Publication number Publication date
WO2007054969A3 (en) 2007-11-01
WO2007054969A2 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
AU2005276619B2 (en) Lercanidipine salts
WO2007054969A2 (en) Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride
AU2002327924B2 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
EP3337786A1 (en) Asymmetric bisamidation of malonic ester derivatives
WO2016108206A2 (en) Processes for preparation of idelalisib and intermediates thereof
CZ356797A3 (en) Process for preparing lercanidipin hydrochloride
AU2005310406B2 (en) Optical resolution method of amlodipine
KR20190044652A (en) Method for producing indolecarboxamide compound
CA2622683A1 (en) Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
EP1720869A2 (en) Process for the preparation of cabergoline
MXPA04009426A (en) Pharmacia corporation.
US20100087653A1 (en) Novel process for the preparation of lercanidipine
WO2011117876A1 (en) An improved process for the preparation of amlodipine free base and acid addition salts thereof
MXPA04001073A (en) Solvates of lercanidipine hydrochloride and new crystalline forms of lercanidipine hydrochloride.
JPH0521105B2 (en)
JP2021526531A (en) How to make Refite Glast
KR20200092945A (en) Lenalidomide Crystalline Form
CN115536577B (en) Preparation method of amlodipine alkali
EP4330255A1 (en) Processes for the synthesis of valbenazine
KR20100063915A (en) Method of preparing s-(-)-amlodipine with high optical purity and intermediate compound produced during the same
JP2009526030A (en) CABERGOLINE AND METHOD FOR PRODUCING NOVEL POLYMORPHIM FORM
JPH0967347A (en) Cyclic amine derivative and medicinal composition containing the same
CN112135820A (en) Novel process for preparing diaminopyrimidine derivatives or their acid addition salts
JP2010526126A (en) Method for producing valsartan
JPH072774A (en) Dihydropyridine derivative, its production, medicine composition containing the same and use of the same derivative for producing therapeutic agent for hypertension

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080521

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20081114

RTI1 Title (correction)

Free format text: PROCESS FOR THE PREPARATION OF LERCANIDIPINE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120731